Topics

Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in Late-Stage Rheumatoid Arthritis Studies

10:27 EDT 11 Oct 2019 | Speciality Pharma Journal

FOSTER CITY, Calif. & MECHELEN, Belgium–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of moderately-to-severely active rheumatoid arthritis (RA) are consistent with and …

Original Article: Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in Late-Stage Rheumatoid Arthritis Studies

NEXT ARTICLE

More From BioPortfolio on "Gilead and Galapagos Announce Efficacy and Safety Results of Filgotinib Through 52 Weeks in Late-Stage Rheumatoid Arthritis Studies"

Quick Search